



Organic Synthesis of Drug-Like Antimicrobial Compounds

Guest Editors:

Prof. Dr. Diana Camelia Nuta

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, "Carol Davila" University of Medicine and Pharmacy, 6 Traian Vuia, 020956 Bucharest, Romania

Prof. Dr. Carmen Limban

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, "Carol Davila" University of Medicine and Pharmacy, 6 Traian Vuia, 020956 Bucharest, Romania

Deadline for manuscript submissions:

closed (15 May 2024)

Message from the Guest Editors

Antimicrobials represent a crucial innovation in the field of medicine and possess the potential to significantly reducing the mortality and morbidity associated with infectious diseases. Regrettably, the excessive and inappropriate use of antimicrobials in human medicine, as well as in agriculture and veterinary practices, has led to the emergence, proliferation, and spread of antimicrobial resistance (AMR).

The topic of AMR is further compounded by microbial biofilms, which exhibit significantly higher tolerance to antimicrobial agents compared to their planktonic counterparts, sometimes even reaching levels hundreds or thousands of times greater.

The emergence of bacterial infections and the spread of antimicrobial resistance have raised serious global concerns, necessitating urgent action to develop innovative and effective antibacterial strategies. One such approach involves continued efforts to incentivize the design and synthesis of new molecules as potential antimicrobial candidates.

Sharing the findings in this research field will undoubtedly contribute to better preparing the scientific community for the potential challenges of the so-called "post-antibiotic era."





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi